RecruitingNCT06535451

Lung Cancer Screening Program in Mexico

Lung Cancer Early Detection With Low-dose Computed Tomography in High-risk Individuals: Experience in Mexico

Sponsor

Instituto Nacional de Cancerologia de Mexico

Enrollment

1,000 participants

Start Date

Mar 24, 2022

Study Type

OBSERVATIONAL

Conditions

Lung Cancer

Summary

This prospective study aims to detect early-stage lung cancer using low-dose computed tomography (LDCT) in Mexicans aged 50 or older who are current or former heavy smokers, non-smokers exposed to significant wood smoke, or diagnosed with COPD. Annual LDCT, spirometry, and serum biomarker tests will be conducted over 3 years, and a follow-up lasting up to 10 years.

Eligibility

Min Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This is a lung cancer early detection program in Mexico that uses low-dose CT scans to screen high-risk people before symptoms appear. Early detection gives patients much better treatment options and survival rates. **You may be eligible if...** - You are over 50 years old - You currently smoke or smoked heavily (20+ pack-years) and quit within the last 15 years - You have been exposed to wood smoke for more than 100 hours per year (non-smoker) - You have been diagnosed with COPD (chronic obstructive pulmonary disease) **You may NOT be eligible if...** - You cannot have a CT scan due to physical limitations such as weight - You have been diagnosed with any cancer in the last 5 years (except certain skin cancers) - You have symptoms that might suggest cancer already exists - Your overall health or emotional condition would prevent reliable follow-up Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERScreening

Annual LDCT, lung function test (spirometry), anxiety/depression assessments, and serum biomarkers tests over 3 years. Follow-up will continue for 5 and 10 years or until event completion (cancer diagnosis, end of follow-up, or death).